Figure 1 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer

Figure 1 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer

<p>Discovery of M4205, a potent inhibitor of disease-relevant KIT-mutant variants. <b>A,</b> Schematic overview of clinically observed mutations in different domains of the RTK KIT and estimated target coverage (green: positive; red: negative) of approved and investigational KIT in...

Olles dieđut

Furkejuvvon:
Bibliográfalaš dieđut
Váldodahkki: Christina Esdar (16424072) (author)
Eará dahkkit: Nina Linde (16424066) (author), Andreas Blum (21644608) (author), Hanno Schieferstein (21644611) (author), Christine Drechsler (16424069) (author), Eva Sherbetjian (21644614) (author), Carl Petersson (21644617) (author), Edith Ross (21644620) (author), Birgitta Leuthner (17885856) (author), Ulrich Grädler (21644623) (author), Dieter Dorsch (21644626) (author), Andree Blaukat (15088980) (author)
Almmustuhtton: 2025
Fáttát:
Cancer
Cancer Biology
Therapeutic Research and Development
Oncogenes & Tumor Suppressors
Oncogenes
Sarcomas
Small Molecule Agents
Kinase inhibitors
Fáddágilkorat: Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Geahča maid